Observation of the third quarterly report: The pharmaceutical company's children's drug revenue increased, and its total revenue declined

【Pharmaceutical Network Industry News】On the evening of October 19, Poinsettia released its 2022 third quarter report
.
In the first three quarters of this year, the company achieved revenue of 1.
615 billion yuan, a year-on-year decrease of 2.
32%.

The company attributed the decrease in total revenue to the impact of
the pandemic.
However, from the perspective of product field division, the company's advantages in children's drug products initially appeared in the first three quarters of 2022, achieving operating income of 950 million yuan, a year-on-year increase of 17.
42%.

Among them, the income of children's drugs such as levocetirizine hydrochloride oral drops and montelukast sodium granules increased
rapidly year-on-year.
According to the data, Poinsettia focuses on the field of children's drugs and chronic disease drugs, focusing on drug research and development, production and sales, and its product categories cover chemical drugs, characteristic traditional Chinese medicines, biological vaccines, etc.
, and has built a product pipeline with children's drug products and chronic disease drug products as the core and biological gene vaccine products as the extension, forming a business development pattern
focusing on "characteristic children's drugs + innovative chronic disease drugs + biological gene vaccines" 。 Up to now, in addition to poinsettia, a number of children's medicine companies have released data related to the first three quarters of 2022, and many companies have achieved double growth in revenue and net profit, such as Jichuan Pharmaceutical, China Resources Sanjiu, Jianmin Group, Jiangzhong Pharmaceutical, Sunflower Pharmaceutical, etc
.
Among them, Jichuan Pharmaceutical recently issued an announcement that from January to September 2022, after the company's preliminary calculation, Jichuan Pharmaceutical achieved operating income of about 5.
9 billion yuan, a year-on-year increase of about 9%; The net profit attributable to the parent was about 1.
6 billion yuan, a year-on-year increase of about
25%.
In the third quarter of 2022, the company achieved operating income of about 2 billion yuan, a year-on-year increase of about 17%; The net profit attributable to the parent was about 580 million yuan, a year-on-year increase of about
38%.
The data shows that the total sales revenue of Jichuan Pharmaceutical's products Pudi Blue anti-inflammatory oral liquid, rabeprazole sodium enteric-coated capsules, and pediatric soybean Qingqing heat granules accounted for 69.
99%
of the main business income.
Behind the growth of the performance of Jichuan Pharmaceutical, it is inseparable from the company's continuous increase in innovative scientific research, in the first half of this year, the company's research and development achievements were outstanding, and it has successively obtained magnesium, sodium and potassium sulfate oral concentrated solution, Oprinon hydrochloride injection production approval, Qifeng's granule drug registration and filing notice, completed ibuprofen suspension, azithromycin dry suspension declaration and production, etc
。 According to data from the State Food and Drug Administration, among the more than 6,000 pharmaceutical factories in China, there are only about 10 enterprises specializing in the production of children's drugs, and among the existing more than 3,500 kinds of drugs, only more than 60 kinds are specially used by children, accounting for about 1.
7%
of the entire variety of pharmaceutical preparations.
In the eyes of the industry, for children's drugs, R&D and innovation is an unavoidable challenge, and pharmaceutical companies need to continue to enrich product lines, constantly innovate and upgrade products to meet the new needs
of children's drugs.
In addition to Jichuan Pharmaceutical, Jianmin Group said in this year's semi-annual report that it will increase investment in research and development, accelerate the development and establishment of new products, and orderly promote the secondary development of
old products.
From the perspective of the children's drug market environment, in order to ensure the healthy growth of children, China actively encourages the development of special drugs for children, and favorable policies have been frequently introduced
in recent years.
With the rapid advancement of the "Healthy China" initiative, the environment for children's drug research and development is improving, and changes in the disease spectrum will also give birth to new market opportunities
for children's medicine.
Statistics show that the market size of children's drugs in China will be about 185.
6 billion yuan in 2020, and it is expected that the scale of China's children's drug market will exceed 200 billion yuan
in 2022.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.